Phaim Phaim

Press and Publications

We'd love to tell you more about what we do at Phaim and how we look to develop treatments that change how we prevent and treat type 1 diabetes as well as other autoimmune diseases.

YouTube Video

Phaim Pharma poised to trial drug that resets immune system to treat T1D.

In The News

A novel method assessing the success of any diabetes intervention therapy published in 2020.

Editorial

Background to AIM

Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1.

Read Here

Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy.

Read Here

Reduction in CD4 Central Memory T-Cell Subset in Costimulation Modulator Abatacept-Treated Patients With Recent-Onset Type 1 Diabetes Is Associated With Slower C-Peptide Decline.

Read Here

Antigen-based therapy with glutamic acid decarboxylase (GAD) AIM therapy in patients with recent-onset type 1 diabetes: a randomised double-blind trial.

Read Here

Extreme Th1 bias of invariant V—24J—Q T cells in type 1 diabetes.

Read Here

Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus.

Read Here

Concordance for Islet Autoimmunity among Monozygotic Twins.

Read Here

New hope for immune intervention therapy in type 1 diabetes.

Read Here

Current Publications supporting AIM

A Novel Quantitative Approach to Staging and Assessing Recovery from Type 1 Diabetes Mellitus: The Type 1 Diabetes Mellitus Metabolic Recovery Index.

Read Here

Antigen-specific tolerance to self-antigens in protein replacement therapy, gene therapy and autoimmunity.

Read Here

Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C- peptide in patients with type 1 diabetes.

Read Here

Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device.

Read Here